Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2002

View Archived Issues

DB-289 enters phase II trial for PCP in HIV/AIDS patients

Third phase III trial under way for INS-365 Ophthalmic in dry eye

Promising profile reported at AACR meeting for novel histone deacetylase inhibitor CG-1521

LAQ-824: a potential new antitumor agent acting via inhibition of histone deacetylase

Novel RXR agonist characterized at ACS meeting by GSK

Flt-3 kinase inhibitors and potential for treatment of AML discussed in Orlando by Millennium

Favorable pharmacokinetic profile seen for novel tyrosine kinase inhibitor CHIR-200131

Orally active VEGF receptor tyrosine kinase-selective agent presented at AACR meeting

Independent review and long-term follow-up of phase II Orathecin study

ACS news: Abbott describes discovery of new series of PTP1B inhibitors

Potent, selective, nonpeptide PTP1B inhibitors discovered in Novo Nordisk/Ontogen joint effort

Adherex and AstraZeneca extend Exherin collaboration agreement

European Commission designates E21R orphan drug in JMML

IAVI-sponsored AIDS vaccines enter phase II

Gliatech receives grant for selective GlyT1 inhibitor development

Collateral updates achievements of 2001

Preclinical data discussed this week support clinical trials with thioplatin

WX-G250 and WX-G250RIT designated orphan drugs for renal cell carcinoma in E.U.

Inhibitors of uPA with favorable PK properties described in patent literature

New vascular damaging agents in development at Angiogene Pharmaceuticals

Neurogen patents new series for CNS disorders

Potent and selective uPA inhibitors designed by Corvas scientists

Streptomyces strain discovered to produce new antitumor compounds

Antiherpesvirus agents jointly prepared by Pfizer and JT

Japan Tobacco patents analgesic thiazole compounds

Gene-based therapy EG-009 designated orphan drug for high-grade glioma

FDA approves SecreFlo for diagnosis of pancreatic dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...